Patient Scenario 1: RR DTC Managed With Frontline Lenvatinib

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.

Related Keywords

Marcia Brose , , Treatment Approaches , Sequencing Strategies , Differentiated Thyroid Cancer , With Frontline Lenvatinib , Thyroid Cancer , Dtc Cancer , Dtc , Rr Dtc , Radioiodine Refractory , Radioiodine Refractory Dtc , Lenvatinib , First Line Therapy , First Line Treatment , Dose Reduction , Dose Adjustment , Lenvatinib Dosing , Adverse Events , Drug Adverse Event , Hypertension Management ,